| Literature DB >> 35336178 |
Katharina Meissner1, Carola Sauter-Louis1, Stefan E Heiden2, Katharina Schaufler2,3, Herbert Tomaso4, Franz J Conraths1, Timo Homeier-Bachmann1.
Abstract
Antimicrobial resistance is an increasing global problem and complicates successful treatments of bacterial infections in animals and humans. We conducted a longitudinal study in Mecklenburg-Western Pomerania to compare the occurrence of ESBL-producing Escherichia (E.) coli in three conventional and four organic pig farms. ESBL-positive E. coli, especially of the CTX-M type, were found in all fattening farms, confirming that antimicrobial resistance is widespread in pig fattening and affects both conventional and organic farms. The percentage of ESBL-positive pens was significantly higher on conventional (55.2%) than on organic farms (44.8%) with similar proportions of ESBL-positive pens on conventional farms (54.3-61.9%) and a wide variation (7.7-84.2%) on organic farms. Metadata suggest that the farms of origin, from which weaner pigs were purchased, had a major influence on the occurrence of ESBL-producing E. coli in the fattening farms. Resistance screening showed that the proportion of pens with multidrug-resistant E. coli was similar on conventional (28.6%) and organic (31.5%) farms. The study shows that ESBL-positive E. coli play a major role in pig production and that urgent action is needed to prevent their spread.Entities:
Keywords: antimicrobial resistance; extended-spectrum ß-lactamase-producing Escherichia coli; organic farming; pig
Year: 2022 PMID: 35336178 PMCID: PMC8950372 DOI: 10.3390/microorganisms10030603
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Location of sampled farms in the federal state of Mecklenburg-Western Pomerania. Conventional fattening farms are depicted in red and organic ones in green. The district names are indicated in light gray (HRO = Hansestadt Rostock, LRO = Rostock-Land, LUP = Ludwigslust-Parchim, MSE = Mecklenburgische Seenplatte, NWM = Nordwest-Mecklenburg, SN = Schwerin, VG = Vorpommern-Greifswald, VR = Vorpommern-Rügen).
Figure 2Average proportion of ESBL-positive pens per fattening pig farm in Mecklenburg-Western Pomerania (grey bars = conventional farms, grey bordered bars = organic farms; error indicators represent the 95% confidence intervals).
Proportions of ESBL-positive pens and runs in organically managed fattening pig farms in Mecklenburg-Western Pomerania per farm and farm visit in percent.
| Sampling 1 | Sampling 2 | Sampling 3 | Sampling 4 | Sampling 5 | |
|---|---|---|---|---|---|
| Farm 1 | 100% (13/13) | 100% (14/14) | 6.7% (1/15) | 28.6% (4/14) | 76.9% (10/13) |
| Farm 2 | 100% (7/7) | 28.6% (2/7) | 71.4% (5/7) | 0.0% (0/7) | 71.4% (5/7) |
| Farm 3 | 66.7% (2/3) | 100% (4/4) | 16.7% (1/6) | 100% (4/4) | 50.0% (2/4) |
| Farm 4a | 0.0% (0/2) | 50.0% (1/2) | 0.0% (0/2) | 0.0% (0/3) | 0.0% (0/3) |
| Farm 4b | 100% (2/2) | 66.7% (2/3) | 75.0% (3/4) | 100% (5/5) | 60.0% (3/5) |
| Farm 5 | 50.0% (2/4) | 71.4% (5/7) | 57.1% (4/7) | 9.1% (1/11) | 81.8% (9/11) |
| Farm 6 | 100% (3/3) | 75.0% (4/4) | 0.0% (0/4) | 33.3% (1/3) | 100% (1/1) |
| Farm 7 | 0.0% (0/6) | 16.7% (1/6) | 28.6% (2/7) | 0.0% (0/7) | 12.5% (1/8) |
Bacteriologically positive samples in fattening pigs and results of resistance screening. 3-MDR = isolates resistant to penicillin and cephalosporins and at least one other class of antibiotics; 5-MDR = isolates resistant to penicillin and cephalosporins and at least three other classes of antibiotics.
| Farm | Number of Tested Samples | Resistance Screening | |||
|---|---|---|---|---|---|
| Number of Tested Isolates * | 3-MDR | 5-MDR | Resistant to Ciprofloxacin | ||
| 1 | 106 | 41 | 15 (36.6%) | 2 (4.9%) | 4 (9.8%) |
| 2 | 98 | 34 | 11 (32.4%) | 2 (5.9%) | 3 (8.8%) |
| 3 | 113 | 23 | 20 (87.0%) | 4 (17.4%) | 5 (21.7%) |
| 4a | 113 | 0 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 4b | 132 | 48 | 46 (95.8%) | 7 (14.6%) | 19 (39.6%) |
| 5 | 240 | 58 | 13 (22.4%) | 1 (1.7%) | 2 (3.4%) |
| 6 | 134 | 24 | 23 (95.8%) | 2 (8.3%) | 12 (50.0%) |
| 7 | 200 | 10 | 9 (90.0%) | 0 (0.0%) | 7 (70.0%) |
* i.e., phenotypically cefotaxime-resistant E. coli.
Resistance profiles in the VITEK 2 Compact study of 51 isolates derived from pigs in finishing fattening (≥90 d in fattening). Isolates with identical results in AST from one farm were summarized to a resistance profile. (Con = conventional farm; Org = organic farm, S = sensitive, I = intermediate, R = resistant).
| Farm 1 (Con) | Farm 2 (Con) | Farm 3 (Con) | Farm 4b (Org) | Farm 5 (Org) | Farm 6 (Org) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ampicillin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Amoxicillin/Clavulanic acid | S | S | S | S | S | S | S | S | S | I | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Piperacillin | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Piperacillin/Tazobactam | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Cefuroxime | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Cefotaxime | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| Ceftazidime | R | S | S | S | R | S | S | S | S | S | S | R | S | R | S | R | S | S | S | S | R | S | S | S |
| Cefepime | R | S | S | S | R | S | S | S | S | S | S | R | S | S | S | S | S | S | S | S | S | S | R | S |
| Gentamicin | R | S | S | S | R | S | S | I | S | S | S | R | S | S | S | S | S | S | S | S | S | S | S | S |
| Amikacin | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Tobramycin | I | S | S | S | I | S | S | R | S | S | S | I | S | S | S | S | S | S | S | S | S | S | S | S |
| Ciprofloxacin | R | S | S | S | R | S | S | S | S | S | S | R | R | S | S | S | S | S | S | S | S | S | S | S |
| Moxifloxacin | R | S | S | S | R | S | S | S | S | S | S | R | R | R | S | R | S | R | S | S | S | R | R | R |
| Fosfomycin | S | S | S | S | S | S | S | I | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Nitrofurantoin | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | I | S | S | S | S | S | S | S |
| Trimethoprim | R | R | S | S | R | R | R | S | R | S | S | R | S | S | S | R | S | S | S | S | S | S | S | S |
| Trimethoprim/Sulfamethoxazole | R | R | S | S | R | R | R | R | R | S | S | R | S | S | S | R | S | S | S | S | S | S | S | S |
| Aztreonam | R | R | R | S | R | R | S | I | S | S | S | R | R | S | S | R | S | S | S | S | S | S | R | R |
| Imipenem | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Meropenem | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Ertapenem | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Tigecycline | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| Colistin | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |